VESSEL DUE F 600 LSU AMPOULE

Χώρα: Μαλαισία

Γλώσσα: Αγγλικά

Πηγή: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Δραστική ουσία:

SULODEXIDE

Διαθέσιμο από:

EP PLUS GROUP SDN. BHD.

INN (Διεθνής Όνομα):

SULODEXIDE

Μονάδες σε πακέτο:

10Units Units

Κατασκευάζεται από:

ALFASIGMA S.p.A

Φύλλο οδηγιών χρήσης

Not Applicable

Αρχείο Π.Χ.Π.

Antithrombotic drugs
Vessel Due F ampoules: Each ampoule contains: Sulodexide 600 LSU
Excipients: sodium chloride, water for injection.
Vessel Due F capsules: Each capsule contains: Sulodexide 250 LSU
Excipients: sodium lauryl sarcosinate, silicon dioxide, triacetin, gelatine, glycerol, sodium ethyl
parahydroxybenzoate, sodium propyl parahydroxybenzoate, titanium dioxide E171, red iron oxide E172.
Mechanisms of action:
Sulodexide has a relevant antithrombotic activity both in rats and rabbits. In the case of rats, Sulodexide is
able to prevent the formation of venous and arterial thrombus; it is also effective in reducing the weight of
pre-formed thrombi both by parenteral and oral administration.
The antithrombotic activity is related to:
a) A block of thrombin and cathepsin G platelet aggregation;
b) Inhibitory effect on platelet adhesives;
c) A block in platelet function;
d) Anticoagulant and pro-fibrinolytic activity shown both in vivo and in vitro in animals and in humans.
The mechanism of action of the antithrombotic activity is due to the simultaneous inhibition of circulating
thrombin through its affinity for anti-thrombin III and the thrombin bound to surfaces, such as the surface
of the thrombus, as well as through affinity for heparin cofactor II. This simultaneous action which catalyses
the thrombin inhibition reaction seems to be better than that observed with heparin and increases the
antithrombotic potential of Sulodexide. Furthermore, Sulodexide causes less bleeding than conventional
heparin at doses which are active on thrombosis. Affinity for fibrin both in vitro and in vivo, both after
intravenous and oral administration has been shown; in fact, Sulodexide labeled with fluorescent binds to
the fibrin of the thrombus and it is found to be still bound even several hours after administration. This
observation could mean that Sulodexide is able to carry out its antithrombotic action locally on the thrombus.
Sulodexide shows an anti-atherosclerotic activity in experimental models in rabbits.
The pha